Acute Sensorineural Hearing Loss - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 47 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Acute Sensorineural Hearing Loss - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Acute Sensorineural Hearing Loss - Pipeline Review, H2 2014', provides an overview of the Acute Sensorineural Hearing Loss's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Sensorineural Hearing Loss, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Sensorineural Hearing Loss and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Sensorineural Hearing Loss
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acute Sensorineural Hearing Loss and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acute Sensorineural Hearing Loss products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Sensorineural Hearing Loss pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Sensorineural Hearing Loss
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Sensorineural Hearing Loss pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Acute Sensorineural Hearing Loss Overview 6
Therapeutics Development 7
Pipeline Products for Acute Sensorineural Hearing Loss - Overview 7
Pipeline Products for Acute Sensorineural Hearing Loss - Comparative Analysis 8
Acute Sensorineural Hearing Loss - Therapeutics under Development by Companies 9
Acute Sensorineural Hearing Loss - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Acute Sensorineural Hearing Loss - Products under Development by Companies 13
Acute Sensorineural Hearing Loss - Companies Involved in Therapeutics Development 14
Nordmark Arzneimittel GmbH & Co. KG 14
Orbis Biosciences, Inc. 15
Otologic Pharmaceutics, Inc. 16
Pfizer Inc. 17
Sound Pharmaceuticals, Inc. 18
Xigen SA 19
Acute Sensorineural Hearing Loss - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
(acetylcysteine + disufenton sodium) - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ancrod - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
betamethasone valerate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
PF-04958242 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecules to Inhibit Gamma Secretase for Sensorineural Hearing Loss - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
SPI-1005 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Stem Cell Therapy for Sensorineural Hearing Loss - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
XG-102 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Acute Sensorineural Hearing Loss - Recent Pipeline Updates 41
Acute Sensorineural Hearing Loss - Product Development Milestones 43
Featured News & Press Releases 43
Nov 19, 2014: Otologic Pharmaceutics Initiates Phase 1 Clinical Study of NHPN-1010 for Hearing Disorders 43
Feb 18, 2014: Sound Pharmaceuticals submits positive Phase 2 clinical trial data on SPI-1005 for the prevention and treatment of sensorineural hearing loss 43
Dec 05, 2012: University Of Florida Begins Phase-II Trial With Sound Pharma's SPI-1005 To Prevent Hearing Loss 44
Nov 13, 2012: Auris Medical Announces Positive Results From Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss 44
Apr 20, 2012: Auris Medical Completes Enrolment In Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Number of Products under Development for Acute Sensorineural Hearing Loss, H2 2014 7
Number of Products under Development for Acute Sensorineural Hearing Loss - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Acute Sensorineural Hearing Loss - Pipeline by Nordmark Arzneimittel GmbH & Co. KG, H2 2014 14
Acute Sensorineural Hearing Loss - Pipeline by Orbis Biosciences, Inc., H2 2014 15
Acute Sensorineural Hearing Loss - Pipeline by Otologic Pharmaceutics, Inc., H2 2014 16
Acute Sensorineural Hearing Loss - Pipeline by Pfizer Inc., H2 2014 17
Acute Sensorineural Hearing Loss - Pipeline by Sound Pharmaceuticals, Inc., H2 2014 18
Acute Sensorineural Hearing Loss - Pipeline by Xigen SA, H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Assessment by Combination Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Acute Sensorineural Hearing Loss Therapeutics - Recent Pipeline Updates, H2 2014 41